BNTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Biontech SE (BNTX) looks like a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. The stock has a constructive technical setup, positive analyst sentiment, and meaningful oncology pipeline catalysts that support a long-term re-rating. It is not a pure momentum trade, but the current price is near resistance and still offers a reasonable entry for a patient long-term investor who wants exposure now rather than waiting.
BNTX is trending positively in the short term. MACD histogram is 0.907 and expanding above zero, which supports upside momentum. RSI_6 at 79.365 suggests the stock is extended in the near term, but the move is still backed by improving momentum rather than weakness. Moving averages are converging, implying a possible trend transition or consolidation near current levels. Price is trading around 97.845, just above pivot 93.275 and near R1 at 97.089, with next resistance at 99.446. Support sits at 89.461, which gives the chart a decent risk-reward structure for a long-term entry.
["UBS upgraded BNTX to Buy and raised its target to $135, citing increased conviction in the oncology pipeline and near-term clinical catalysts.", "Berenberg and Canaccord both maintained Buy ratings, signaling continued Wall Street support for the long-term oncology story.", "BioNTech has a large cash position, which supports pipeline development and strategic flexibility.", "Positive Phase 2 data for T-Pam in endometrial cancer was viewed favorably by BofA and supports oncology pipeline value.", "Recent share strength and positive momentum suggest the market is starting to price in pipeline progress."]
["Revenue has declined sharply from the COVID-era peak, and the company is still transitioning away from that legacy business.", "Some analysts lowered price targets, reflecting discontinuations and pipeline changes over the past year.", "Hedge fund and insider trading trends are neutral, so there is no strong informed-money buying signal.", "The latest news flow includes older revenue decline commentary, showing the business is still in a transition phase."]
The latest quarter financial snapshot was unavailable due to an error, so I cannot verify the most recent reported quarter details from the provided data. Based on the news summary, BioNTech reported a 35.4% year-over-year revenue decline to €118.1 million in the referenced period, which shows pressure in the legacy COVID business. At the same time, the company continues to run a large oncology pipeline with more than 25 phase 2 and phase 3 trials, which is the key long-term growth driver. Latest quarter season was not provided.
Analyst sentiment is clearly constructive. UBS upgraded the stock to Buy with a $135 target. Berenberg kept Buy and set $140, noting the stock deeply undervalues the oncology pipeline. Canaccord also kept Buy at $158, though it trimmed the target due to program changes. BofA raised its target to $130 and stayed Buy after positive Phase 2 data, while Morgan Stanley kept Overweight with a $126 target. Overall, Wall Street pros are positive because they see the oncology pipeline and cash position as the main upside drivers, while the main con is the ongoing decline in the COVID business.
